ABS1149 INTERIM ANALYSIS OF A EUROPEAN REAL-WORLD STUDY ON THE EFFECTIVENESS, PHYSICIAN SATISFACTION, AND PATIENT CHARACTERISTICS IN AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: INSIGHTS FROM GERMANY, SPAIN, AND THE UNITED KINGDOM

Background: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A and has demonstrated long-term clinical efficacy and safety in patients with active axial spondyloarthritis (axSpA) [1, 2]. BKZ was approved for the treatment of axSpA in Europe in 2023 [3]. Real-world research can complement findings from randomised controlled trials by evaluating the effectiveness of treatments in a broader population. Objectives: To assess effectiveness, patient characteristics, treatment history, disease severity, and physician satisfaction among patients with axSpA treated with BKZ, from a real-world cross-sectional study. Methods: Interim data were drawn from the Adelphi Real World BKZ axSpA Plus Disease Specific Programme™, an ongoing cross-sectional survey, with elements of retrospective data collection, from both rheumatologists and their consulting patients with axSpA undergoing BKZ treatment. This is a multinational survey being conducted in France, Germany, Italy, Spain, the United Kingdom (UK), Canada, Japan, and the United States of America. Data collection began in July 2024, following a staggered approach by country based on BKZ reimbursement, and is expected to be complete in February 2026. Rheumatologist-reported interim data from Germany, Spain and the UK is presented in this abstract. Rheumatologists reported details of demographics, treatment history, perceived overall disease severity, and their own satisfaction with the control provided by BKZ. Rheumatologist-perceived disease severity at the time of data collection (‘currently') and retrospectively at the point of initiating the current treatment was physician-judged with no clinical definition applied. Rheumatologists may have considered multiple factors when subjectively assessing a patient's disease. Rheumatologist-reported severity and treatment satisfaction data were stratified by BKZ treatment duration (<3 months, 3–6 months, >6 months). No inclusion criteria relating to treatment duration were imposed. All analyses were descriptive and data were reported as observed; no imputation of missing values was performed. Results: Demographics, disease duration and treatment history for all patients with axSpA treated with BKZ (n=325) are described in the Table 1. The sample was comprised of patients from Germany (40%), Spain (29%) and the UK (31%), with an almost equal split of patients diagnosed with radiographic (r-) axSpA (53%) and non-radiographic (nr-) axSpA (47%). Participating rheumatologists (n=73) reported all patients to have moderate-to-severe disease at BKZ initiation (Figure 1A). At the most recent consultation, in patients who had been prescribed BKZ for <3 months, 3–6 months or >6 months, 26%, 63% and 72%, respectively, were perceived to have mild disease. In patients who had received at least 3 months of treatment, only 2% were perceived as having severe disease. At this same consultation, in patients who had been prescribed BKZ for <3 months, 3–6 months, or >6 months, 93%, 93% and 97% of physicians, respectively, reported to be satisfied or very satisfied with treatment (Figure 1B). Conclusion: In real-world settings, physician-perceived disease severity was seen to improve in patients with axSpA treated with BKZ, even when prescribed for less than three months, with sustained treatment of three months or more yielding the largest improvements. Nearly all rheumatologists were satisfied with the control over axSpA provided by BKZ in their patients, with the highest level of physician-reported satisfaction (97%) observed in the group treated for more than 6 months. These findings confirm the effectiveness of BKZ in axSpA in routine clinical practice. REFERENCES: [1] Baraliakos X, Deodhar A, Van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Fleurinck C, Vaux T. 2024. Annals of the Rheumatic Diseases 2024;83:913-14. [2] Baraliakos X, Deodhar A, Dougados M, Gensler LS, Molto A, Ramiro S, Kivitz AJ, Poddubnyy D, Oortgiesen M, Vaux T, Fleurinck C. Arthritis & Rheumatology 2022;74(12):1943-58. [3] UCB Pharma S.A. Bimzelx© (bimekizumab): Summary of Product Characteristics. 2023. https://www.ema.europa.eu/en/medicines/hu man/EPAR/bimzelx (accessed: 28 November 2024). Table 1 . Acknowledgements: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the BKZ axSpA Plus Disease Specific Programme (DSP™). The DSP is a wholly owned Adelphi product and is the intellectual property of Adelphi Real World. The analysis described here were funded by UCB and used data from the Adelphi BKZ axSpA Plus DSP. UCB was one of multiple subscribers to the DSP and did not influence the original survey through either contribution to the design of questionnaires or data collection. Publication coordination was provided by Costello Medical and supported by UCB. Disclosure of Interests: Denis Poddubnyy Speaker for AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer and UCB, Consultant for AbbVie, Biocad, Eli Lilly, Gilead, GSK, MSD, Moonlake, Novartis, Pfizer, Samsung Bioepis and UCB, Grant/research support from AbbVie, Lilly, MSD, Novartis and Pfizer, Xenofon Baraliakos Paid instructor for AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB, Speakers bureau from AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB, Consultancy fees from AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer and UCB, Grant/research support from Abbvie, Celltrion, Janssen and Novartis, Steven Zhao Speaker for Novartis, UCB, AlfaSigma and AbbVie, Consultancy for Novartis, UCB, AlfaSigma and AbbVie, Clementina López-Medina Speakers bureau for AbbVie, Eli Lilly, Janssen, MSD, Novartis and UCB, Consultant for Eli Lilly, Novartis and UCB, Grant/research support from AbbVie, Eli Lilly, Novartis and UCB, Isabel Truman Employee of Adelphi Real World, Dan Twigg Employee of Adelphi Real World, Hervé Besson Shareholder of UCB, Employee of UCB, Helena Roque Employee of UCB. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.